TASHA DESPAULT: Open Payments
NPI 1740479153 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,261 in 61 payments from 25 companies in 2025. Trend: 2023 $1,238 · 2024 $2,691 · 2025 $1,261
Food & beverage: $1,261
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $218 |
| Lilly USA, LLC | 5 | $98 |
| Bausch Health US, LLC | 5 | $97 |
| Celltrion USA Inc. | 4 | $80 |
| QOL Medical, LLC | 2 | $68 |
| Ipsen Biopharmaceuticals, Inc | 3 | $67 |
| GENZYME CORPORATION | 2 | $67 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $57 |
| Madrigal Pharmaceuticals | 3 | $52 |
| Intercept Pharmaceuticals, Inc. | 3 | $45 |
Products named: LINZESS, DUPIXENT, APLENZIN, OMVOH, VEGZELMA, Sucraid, IQIRVO, RINVOQ.
Industry payments across TX — which companies pay providers there.
